Targets › SYK
7 programs from 7 companies in 8 trials: 5 Phase 1, 2 Phase 2, 1 Phase 3; Hematology, Oncology, Other; next expected readout Nov 2026.
Non-receptor tyrosine kinase which mediates signal transduction downstream of a variety of transmembrane receptors including classical immunoreceptors like the B-cell receptor (BCR). Regulates several biological processes including innate and adaptive immunity, cell adhesion, osteoclast maturation, platelet activation and vascular development. (UniProt, P43405)
Open in Phaseline: the race on SYK, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Chia Tai Tianqing Pharmaceutical Group | TQB3473 Spleen tyrosine kinase (Syk) inhibitor | SYK | Phase 3 | Primary Immune Thrombocytopenia | Mar 2027 |
| Hutchmed | Sovleplenib (HMPL-523) Tyrosine-protein kinase SYK inhibitor | SYK | Phase 2 | Warm Antibody Autoimmune Hemolytic Anemia | Nov 2026 |
| Seoul National University Hospital | Poseltinib Spleen tyrosine kinase (SYK) inhibitor | SYK | Phase 2 | Relapsed/refractory Diffuse Large B Cell Lymphoma | Nov 2026 |
| National Heart, Lung, and Blood Institute (NHLBI) | Fostamatinib Tyrosine-protein kinase SYK inhibitor | SYK | Phase 1 | Sickle Cell Disorders; Lung Transplantation | May 2027 |
| University of California, San Diego | Fostamatinib Tyrosine-protein kinase SYK inhibitor | SYK | Phase 1 | Pancreatic Ductal Adenocarcinoma (PDAC) | Dec 2027 |
| Stefanie Sarantopoulos, MD, PhD. | Fostamatinib Tyrosine-protein kinase SYK inhibitor | SYK | Phase 1 | Chronic Graft Versus Host Disease | Jan 2029 |
| Imperial College London | Fostamatinib Tyrosine-protein kinase SYK inhibitor | SYK | Phase 1 | Renal Transplant Rejection | – |
Primary Immune Thrombocytopenia (1) Sickle Cell Disorders (1) Lung Transplantation (1) Chronic Graft Versus Host Disease (1) Warm Antibody Autoimmune Hemolytic Anemia (1) Pancreatic Ductal Adenocarcinoma (PDAC) (1) Renal Transplant Rejection (1) Relapsed/refractory Diffuse Large B Cell Lymphoma (1)
small molecule (4), protein or peptide (1), antibody (1)
Chia Tai Tianqing Pharmaceutical Group (1) National Heart, Lung, and Blood Institute (NHLBI) (1) Stefanie Sarantopoulos, MD, PhD. (1) Hutchmed (1) University of California, San Diego (1) Imperial College London (1) Seoul National University Hospital (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.